Talk:Beta-2 microglobulin

Isn't 12 month median survival for multiple myeloma out of date?

Beta2microglobulin is used to stage multiple myeloma, so recently diagnosed multiple myeloma patients coming across the statement that for levels > 4 mg/L median survival is "only 12 months" get quite a shock. I certainly did. The reference given is dated 2011, and while it may be historically accurate, I believe this number is significantly out of date due to big advances in treatment of multiple myeloma in the last decade.

I'm an engineer not a doctor so I can't give another reference, but 12 month median survival doesn't correspond to lifetimes I see widely quoted in the literature, nor with the expected survival time I was given by two doctors (several years), nor with my experience, and my beta2microglobulin at diagnosis was 6.9 mg/L, significantly higher than the 4 mg/L threshold. — Preceding unsigned comment added by 98.217.200.163 (talk) 16:13, 2 October 2015 (UTC)

Over-Specialized

This article might be useful in an encyclopedia directed to medical and/or biological professionals. Without further explanations of its jargon it is useless to non-specialists. I came here from the article on multiple myloma, which I had gone to because I wanted to learn more about the disease afflicing a good friend. So far, the only thing I have learned is that doctors don't want to talk to non-MDs, but I knew that already.

So, it's mainly a waste of bandwidth - just static. Too Old (talk) 06:18, 10 June 2008 (UTC)

Also a prognostic factor for follicular lymphoma

According to FL stats serum levels of it is one of the 5 factors or parameters in the FLIP2 criteria. What is the upper limit of normal ? - Rod57 (talk) 17:31, 8 April 2016 (UTC)

Clarify if levels refers to levels in blood serum

Numerous times it mentions 'levels'. - It should clarify if this refers to concentration in blood serum or something else ? - Rod57 (talk) 17:41, 8 April 2016 (UTC)

Mutations of B2M found in lung cancer

[1] says "the B2M mutation was found in 6 to 8 percent of lung cancers. Importantly, the B2M mutation was found to be associated with the loss of the HLA-I complex, which is required for immunosurveillance." - Could mention if get RS ? - Rod57 (talk) 15:37, 25 January 2017 (UTC)

Loss of b2m leads to immune evasion

In connection to the "citation needed" parts, this publication shows that loss of b2m leads to immune evasion: https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.28338 46.189.36.164 (talk) 20:01, 21 September 2019 (UTC)

JgwttJgAgj

Agtpwp 2409:4063:6C1B:FE74:831F:ABCD:DADB:E5A0 (talk) 04:17, 2 April 2022 (UTC)